{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:18:46Z","timestamp":1765585126317,"version":"3.48.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.retram.2025.103533","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:00:12Z","timestamp":1753891212000},"page":"103533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bone marrow vacuolization to curative strategies: Evolving paradigms in VEXAS syndrome management"],"prefix":"10.1016","volume":"73","author":[{"given":"Mahmoud I.","family":"Elbadry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Mabed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.retram.2025.103533_bib0001","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"New Eng J Med"},{"issue":"1","key":"10.1016\/j.retram.2025.103533_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2023.101861","article-title":"VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: a hematologist's point of view","volume":"37","author":"Heiblig","year":"2023","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.retram.2025.103533_bib0003","first-page":"244","article-title":"Spectrum of clonal hematopoiesis in VEXAS syndrome","volume":"142","author":"Gutierrez-Rodrigues","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.retram.2025.103533_bib0004","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3324\/haematol.2021.280238","article-title":"Nevill TJ: VEXAS syndrome in a female patient with constitutional 45, X (Turner syndrome)","volume":"107","author":"Stubbins","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.retram.2025.103533_bib0005","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s11739-023-03193-z","article-title":"VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases","volume":"18","author":"Vitale","year":"2023","journal-title":"Intern Emerg Med"},{"issue":"3","key":"10.1016\/j.retram.2025.103533_bib0006","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1055\/s-0043-1770958","article-title":"VEXAS Syndrome","volume":"10","author":"Zhang","year":"2023","journal-title":"Glob Med Genet"},{"issue":"16","key":"10.1016\/j.retram.2025.103533_bib0007","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/bloodadvances.2021004976","article-title":"Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1","volume":"5","author":"Obiorah","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.retram.2025.103533_bib0008","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/1744666X.2023.2157262","article-title":"An update on VEXAS syndrome","volume":"19","author":"Al-Hakim","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"10.1016\/j.retram.2025.103533_bib0009","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s41375-023-01857-5","article-title":"Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies","volume":"37","author":"Sakuma","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.retram.2025.103533_bib0010","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.14441","article-title":"Bone marrow vacuolization at the crossroads of specialties: molecular insights and diagnostic challenges","author":"Elbadry","year":"2025","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.retram.2025.103533_bib0011","doi-asserted-by":"crossref","first-page":"e828","DOI":"10.1097\/HS9.0000000000000828","article-title":"Quantitative assessment of vacuolization of myeloid precursors in VEXAS syndrome","volume":"7","author":"Rabut","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.retram.2025.103533_bib0012","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2022-169959","author":"Plesa","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.retram.2025.103533_bib0013","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/ejh.13944","article-title":"VEXAS syndrome: a review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation","volume":"110","author":"Cherniawsky","year":"2023","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.retram.2025.103533_bib0014","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/bjd.20805","article-title":"Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients","volume":"186","author":"Georgin-Lavialle","year":"2022","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.retram.2025.103533_bib0015","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood.2022016642","article-title":"Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study","volume":"140","author":"Heiblig","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.retram.2025.103533_bib0016","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.retram.2025.103533_bib0017","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood-2018-10-844621","article-title":"Genetics of MDS","volume":"133","author":"Ogawa","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.retram.2025.103533_bib0018","doi-asserted-by":"crossref","first-page":"9785","DOI":"10.1182\/blood-2022-162397","article-title":"Jadersten M: incidence, clinical associations, and Co-mutation patterns of UBA1 mutations in MDS","author":"Sirenko","year":"2022","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.retram.2025.103533_bib0019","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood.2020010286","article-title":"Novel somatic mutations in UBA1 as a cause of VEXAS syndrome","volume":"137","author":"Poulter","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.retram.2025.103533_bib0020","first-page":"244","article-title":"Spectrum of clonal hematopoiesis in VEXAS syndrome","volume":"142","author":"Gutierrez-Rodrigues","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.retram.2025.103533_bib0021","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1182\/blood.2023023723","article-title":"Germing U: molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes","volume":"144","author":"Sirenko","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.retram.2025.103533_bib0022","article-title":"New scenarios in Vacuoles, E1 enzyme, X linked, autoinflammatory, somatic (VEXAS) syndrome: evolution from myelodysplastic syndrome to acute myeloid leukemia","volume":"71","author":"Battipaglia","year":"2023","journal-title":"Curr Res Transl Med"},{"issue":"26","key":"10.1016\/j.retram.2025.103533_bib0023","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"New Eng J Med"},{"issue":"24","key":"10.1016\/j.retram.2025.103533_bib0024","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNF\u03b1 facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.retram.2025.103533_bib0025","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ccr.2011.10.012","article-title":"IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development","volume":"20","author":"Reynaud","year":"2011","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.retram.2025.103533_bib0026","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.4161\/cc.19978","article-title":"Ubiquitin-activating enzyme UBA1 is required for cellular response to DNA damage","volume":"11","author":"Moudry","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.retram.2025.103533_bib0027","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.yjmcc.2021.07.004","article-title":"Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease","volume":"161","author":"Marnell","year":"2021","journal-title":"J. Mol Cell Cardiol"},{"issue":"4","key":"10.1016\/j.retram.2025.103533_bib0028","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1053\/j.seminhematol.2021.10.004","article-title":"Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?","volume":"58","author":"Kusne","year":"2021","journal-title":"Semin Hematol: 2021"},{"issue":"10","key":"10.1016\/j.retram.2025.103533_bib0029","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/s41588-022-01179-9","article-title":"Single-cell multi-omics of human clonal hematopoiesis reveals that DNMT3A R882 mutations perturb early progenitor states through selective hypomethylation","volume":"54","author":"Nam","year":"2022","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.retram.2025.103533_bib0030","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.3324\/haematol.2018.210856","article-title":"Escape hematopoiesis by HLA-B5401-lacking hematopoietic stem progenitor cells in men with acquired aplastic anemia","volume":"104","author":"Elbadry","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.retram.2025.103533_bib0031","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/s41375-021-01463-3","article-title":"The GPI-anchored protein CD109 protects hematopoietic progenitor cells from undergoing erythroid differentiation induced by TGF-\u03b2","volume":"36","author":"Tanabe","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.retram.2025.103533_bib0032","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/jha2.515","article-title":"Hematopoietic stem progenitor cells with malignancy-related gene mutations in patients with acquired aplastic anemia are characterized by the increased expression of CXCR4","volume":"3","author":"Katagiri","year":"2022","journal-title":"EJHaem"},{"issue":"9","key":"10.1016\/j.retram.2025.103533_bib0033","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/s41375-018-0047-7","article-title":"Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis","volume":"32","author":"Arends","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.retram.2025.103533_bib0034","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10238-022-00866-5","article-title":"Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases","volume":"23","author":"Jachiet","year":"2023","journal-title":"Clin Exp Med"},{"issue":"11","key":"10.1016\/j.retram.2025.103533_bib0035","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1093\/rheumatology\/kead240","article-title":"How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies","volume":"62","author":"Boyadzhieva","year":"2023","journal-title":"Rheumatology"},{"issue":"26","key":"10.1016\/j.retram.2025.103533_bib0036","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1182\/blood.2020010177","article-title":"Therapeutic options in VEXAS syndrome: insights from a retrospective series","volume":"137","author":"Bourbon","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.retram.2025.103533_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.678927","article-title":"Case report: VEXAS syndrome: from mild symptoms to life-threatening macrophage activation syndrome","volume":"12","author":"Staels","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.retram.2025.103533_bib0038","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jdcr.2022.02.022","article-title":"Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome","volume":"23","author":"Goyal","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.retram.2025.103533_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.901063","article-title":"Case report: tocilizumab treatment for VEXAS syndrome with relapsing polychondritis: a single-center, 1-year longitudinal observational study in Japan","volume":"13","author":"Kunishita","year":"2022","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.retram.2025.103533_bib0040","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1136\/annrheumdis-2021-220876","article-title":"Tocilizumab in VEXAS relapsing polychondritis: a single-center pilot study in Japan","volume":"80","author":"Kirino","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.retram.2025.103533_bib0041","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1097\/HS9.0000000000000661","article-title":"Azacytidine treatment for VEXAS syndrome","volume":"5","author":"Raaijmakers","year":"2021","journal-title":"Hemasphere"},{"issue":"4","key":"10.1016\/j.retram.2025.103533_bib0042","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bjh.17893","article-title":"Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry","volume":"196","author":"Comont","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.retram.2025.103533_bib0043","first-page":"15","article-title":"Case report: VEXAS syndrome: an atypical indolent presentation as sacroiliitis with molecular response to azacitidine","author":"Pereira da Costa","year":"2024","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.retram.2025.103533_bib0044","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1002\/hem3.129","article-title":"Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome","volume":"8","author":"Aalbers","year":"2024","journal-title":"Hemasphere"},{"issue":"4","key":"10.1016\/j.retram.2025.103533_bib0045","first-page":"969","article-title":"Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry","volume":"196","author":"Comont","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.retram.2025.103533_bib0046","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.seminhematol.2021.09.001","article-title":"Toward a pathophysiology inspired treatment of VEXAS syndrome","author":"Heiblig","year":"2021","journal-title":"Semin Hematol"},{"issue":"11","key":"10.1016\/j.retram.2025.103533_bib0047","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1007\/s00277-024-05942-2","article-title":"Role of allogeneic hematopoietic cell transplantation in VEXAS syndrome","volume":"103","author":"Dias","year":"2024","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.retram.2025.103533_bib0048","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/bjh.18488","article-title":"Allogeneic haematopoietic stem cell transplantation for VEXAS syndrome: UK experience","volume":"199","author":"Al-Hakim","year":"2022","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.retram.2025.103533_bib0049","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.1002\/ajh.26786","article-title":"Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: data from a prospective series of patients","volume":"98","author":"Mangaonkar","year":"2023","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.retram.2025.103533_bib0050","doi-asserted-by":"crossref","first-page":"S292","DOI":"10.1016\/j.jtct.2023.12.397","article-title":"Pilot prospective study of reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with Vexas syndrome","volume":"30","author":"Mangaonkar","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.retram.2025.103533_bib0051","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1182\/bloodadvances.2023012478","article-title":"Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT","volume":"8","author":"Gurnari","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.retram.2025.103533_bib0052","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1383730","article-title":"Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: a case report and systematic review","volume":"14","author":"Bellman","year":"2024","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.retram.2025.103533_bib0053","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1182\/bloodadvances.2021004749","article-title":"Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience","volume":"6","author":"Diarra","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.retram.2025.103533_bib0054","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood-2023-174385","article-title":"Allogeneic hematopoietic cell transplantation for Vexas syndrome: results of a multicenter study from the chronic malignancies and autoimmune disease working parties of the EBMT","volume":"142","author":"Gurnari","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.retram.2025.103533_bib0055","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41409-021-01544-y","article-title":"Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report","volume":"57","author":"Loschi","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.retram.2025.103533_bib0056","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/bjh.19897","article-title":"Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndrome","volume":"206","author":"Gurnari","year":"2025","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.retram.2025.103533_bib0057","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00277-023-05611-w","article-title":"VEXAS syndrome: complete molecular remission after hypomethylating therapy","volume":"103","author":"Sockel","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.retram.2025.103533_bib0058","doi-asserted-by":"crossref","first-page":"8780","DOI":"10.3390\/ijms22168780","article-title":"NLRP3 Ubiquitination-A new approach to target NLRP3 inflammasome activation","volume":"22","author":"Akther","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.retram.2025.103533_bib0059","article-title":"Ubiquitin ligases in control: regulating NLRP3 inflammasome activation","volume":"30","author":"Beesetti","year":"2025","journal-title":"Front Biosci-Landmark"},{"key":"10.1016\/j.retram.2025.103533_bib0060","first-page":"1","article-title":"Novel use of Siltuximab in a patient with VEXAS Syndrome","author":"C\u00e1ceres-Nazario","year":"2024","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.retram.2025.103533_bib0061","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/s41423-020-00630-3","article-title":"Necroptosis, pyroptosis and apoptosis: an intricate game of cell death","volume":"18","author":"Bertheloot","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.retram.2025.103533_bib0062","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41467-024-44811-4","article-title":"VEXAS syndrome is characterized by blood and tissues inflammasome pathway activation and monocyte dysregulation","volume":"15","author":"Kosmider","year":"2024","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.retram.2025.103533_bib0063","first-page":"283","article-title":"Pathogenesis and inflammaging in myelodysplastic syndrome","volume":"110","author":"Villaume","year":"2025","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.retram.2025.103533_bib0064","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s10495-021-01663-3","article-title":"Release mechanisms of major DAMPs","volume":"26","author":"Murao","year":"2021","journal-title":"Apoptosis"},{"key":"10.1016\/j.retram.2025.103533_bib0065","article-title":"VEXAS anemia is a mosaic erythroblastopenia","author":"Rodrigues","year":"2024","journal-title":"bioRxiv"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245231862500042X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245231862500042X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:15:09Z","timestamp":1765584909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S245231862500042X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S245231862500042X"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2025.103533","relation":{},"ISSN":["2452-3186"],"issn-type":[{"type":"print","value":"2452-3186"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone marrow vacuolization to curative strategies: Evolving paradigms in VEXAS syndrome management","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2025.103533","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103533"}}